Compare BMRN & CAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMRN | CAVA |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | 3221 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 9.6B |
| IPO Year | 1999 | 2023 |
| Metric | BMRN | CAVA |
|---|---|---|
| Price | $55.48 | $88.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 23 |
| Target Price | $88.22 | ★ $89.24 |
| AVG Volume (30 Days) | 1.7M | ★ 2.6M |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.80 | 0.54 |
| Revenue | ★ $1,313,646,000.00 | $1,179,664,000.00 |
| Revenue This Year | $15.02 | $25.71 |
| Revenue Next Year | $12.23 | $20.50 |
| P/E Ratio | ★ $30.52 | $156.15 |
| Revenue Growth | 17.62 | ★ 22.41 |
| 52 Week Low | $50.76 | $43.41 |
| 52 Week High | $66.28 | $97.98 |
| Indicator | BMRN | CAVA |
|---|---|---|
| Relative Strength Index (RSI) | 45.29 | 61.58 |
| Support Level | $51.77 | $62.15 |
| Resistance Level | $56.21 | $90.84 |
| Average True Range (ATR) | 1.36 | 4.16 |
| MACD | 0.08 | 0.19 |
| Stochastic Oscillator | 41.16 | 86.81 |
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Cava Group Inc owns and operates a chain of restaurants. It operates a Mediterranean-inspired fast-casual restaurant brand offering menu items. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: i) CAVA: It includes the operations of all company-owned CAVA restaurants, and ii) CAVA Foods: It includes the production of dips, spreads, and certain dressing bases used in CAVA restaurants as well as sales from the Company's consumer packaged goods business. The company generates the majority of its revenue from the CAVA segment.